Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
1 finding from 1 review
Intervention not reported
Number of participants with exacerbations requiring systemic steroids · children with chronic asthma
The intervention showed no clear difference in number of participants with exacerbations requiring systemic steroids (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of participants with exacerbations requiring systemic steroids · children with chronic asthma
The intervention showed no clear difference in number of participants with exacerbations requiring systemic steroids (moderate certainty).
1 finding from 1 review
Hospital admissions · patients with acute asthma
ICS showed no clear difference in hospital admission compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age compared with systemic steroids (moderate certainty).
2 findings from 1 review
Diastolic blood pressure > 95th percentile at 7 years · Neonates with developing BPD
Inhaled steroids probably leads to lower diastolic blood pressure > 95th percentile at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Ever diagnosed as asthmatic by 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in ever diagnosed as asthmatic by 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Neonates with developing BPD
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic steroids (low certainty).
1 finding from 1 review
Hyperglycaemia · Neonates with developing BPD
Inhaled steroids showed no clear difference in hyperglycaemia compared with systemic steroids (low certainty).
1 finding from 1 review
Hypertension · Neonates with developing BPD
Inhaled steroids may leads to lower hypertension compared with systemic steroids (low certainty).
1 finding from 1 review
General conceptual ability (GCA) score at 7 years The test has a standardisation mean of 100 and SD of 15 · Neonates with developing BPD
Inhaled steroids showed no clear difference in general conceptual ability (GCA) score at 7 years The test has a… compared with systemic steroids (moderate certainty).
1 finding from 1 review
Moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Death or moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Systolic blood pressure > 95th percentile at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in systolic blood pressure > 95th percentile at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
Etanercept showed no clear difference in disease‐specific mortality (time to compared with corticosteroids (low certainty).
1 finding from 1 review